Active ingredientLedipasvirCat. No. P-L029-001CAS 1256388-51-8Family · Pharmaceutical analytical standards
Ledipasvir
An antiviral that inhibits the NS5A protein of the hepatitis C virus, approved in 2014 in a fixed combination with sofosbuvir for chronic hepatitis C. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Together with sofosbuvir it formed the first combination pill approved by the FDA for hepatitis C, and the first regimen that did not require interferon or ribavirin.
Go to the active ingredient →Active ingredientLedipasvirCat. No. P-L029-001CAS 1256388-51-8
Isotopically labelledLedipasvir-d6Cat. No. P-L029-002CAS 2050041-12-6
ImpurityLedipasvir Acetyl Spiro ImpurityCat. No. P-L029-004CAS 2040487-36-1
ImpurityLedipasvir Impurity 1Cat. No. P-L029-005
ImpurityLedipasvir Impurity 2Cat. No. P-L029-006
ImpurityLedipasvir Impurity 3Cat. No. P-L029-007
ImpurityLedipasvir Impurity 4Cat. No. P-L029-008CAS 1256387-87-7
ImpurityLedipasvir Impurity 5Cat. No. P-L029-009
ImpurityLedipasvir Impurity 6Cat. No. P-L029-010CAS 1441670-89-8
ImpurityLedipasvir Impurity 7Cat. No. P-L029-011CAS 1499193-65-5
ImpurityLedipasvir Impurity 8Cat. No. P-L029-012
ImpurityLedipasvir Keto Impurity-2Cat. No. P-L029-013CAS 2040487-43-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.